• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Mirvaso (brimonidine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Mirvaso (brimonidine)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Mirvaso is a once daily topical gel formulation of brimonidine, an alpha-2 adrenergic agonist with potent vasoconstrictive activity.

    Mirvaso is specifically indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.

    Mirvaso is supplied as a gel for topical administration. The recommended dose and administration of Mirvaso is as follows: a pea-size amount once daily to each of the five areas of the face: central forehead, chin, nose, each cheek. Mirvaso topical gel should be applied smoothly and evenly as a thin layer across the entire face avoiding the eyes and lips.

    Clinical Results

    FDA Approval
    The FDA approval of Mirvaso was based on two identical randomized, double-blind, placebo-controlled clinical trials The trials were conducted in 553 subjects aged 18 years and older who were treated once daily for 4 weeks with either Mirvaso topical gel or placebo. The primary efficacy endpoint in both pivotal trials was 2-grade Composite Success, defined as the proportion of subjects with a 2-grade improvement on both Clinical Erythema Assessment (CEA) and Patient Self Assessment (PSA) measured at hours 3, 6, 9, and 12 on Day 29. The results are as follows (Mirvaso vs. placebo, respectively): Study 1 Hour 3: 31% vs. 11%; Hour 6: 30% vs. 10%; Hour 9: 26% vs. 10% and Hour 12: 23% vs. 9%. Study 2 Hour 3: 25% vs. 9%; Hour 6: 25% vs. 9%; Hour 9: 18% vs. 11% and Hour 12: 22% vs. 10%.

    Side Effects

    Adverse events associated with the use of Mirvaso may include, but are not limited to the following:

    • erythema
    • flushing
    • skin burning sensation
    • contact dermatitis

    Mechanism of Action

    Mirvaso (brimonidine) is a relatively selective alpha-2 adrenergic agonist. Topical application of Mirvaso gel may reduce erythema through direct vasoconstriction.

    Additional Information

    For additional information regarding Mirvaso or rosacea, please visit the GaldermaUSA web page.

    Approval Date: 2013-08-01
    Company Name: Galderma Labs
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • Virtual Doctoer

      Simple Changes Can Make Trials More Patient Friendly

    • Drug approval

      Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.

    • VaccinewithNeedle-360x240.png

      Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant

    • AskTheExperts-360x240.png

      Ask the Experts: Trial Operations Adjustments in a Remote World

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing